CJC-1295 with DAC is a synthetic analog of growth-hormone-releasing hormone that carries a drug-affinity complex (DAC) — a maleimide group that binds serum albumin — which markedly extends its circulating half-life compared with the non-DAC variant. It is used in laboratories as a tool for studying sustained engagement of the GHRH receptor in model systems.
What DAC changes
By covalently tethering to albumin, the DAC modification converts a short-acting releasing-hormone analog into a long-acting one. This makes it valuable for studying continuous GHRH-receptor engagement, in contrast with the more pulsatile profile of CJC-1295 without DAC. The receptor biology is identical; the pharmacokinetics are not.
Mechanistic class
It engages the same GHRH receptor as sermorelin, so the receptor pharmacology is shared while the duration of action differs substantially. Researchers often study it alongside GHS-R agonists like ipamorelin to compare and combine the two distinct growth-hormone-axis pathways.
Why the design matters
The albumin-binding strategy answers a specific research need: modeling what happens when GHRH-receptor signaling is available continuously rather than in brief bursts. The structural detail behind this is covered in its chemical structure and synthesis article, and its historical development in discovery and history.
Typical research use
Because of its long duration, it suits sustained-exposure and time-course experiments rather than acute pulse studies, giving investigators a way to probe the growth-hormone axis over extended windows.
Research context
Handling of a lyophilized analog follows the general reconstitution procedure, and confirming identity and purity depends on HPLC analysis.
Questions the reagent can address
The DAC analog is most informative when the research question concerns duration: receptor responsiveness during prolonged ligand availability, adaptation of downstream signaling, or differences between continuous and pulse-like exposure. It is less suitable as a direct substitute for native GHRH when physiological timing itself is the variable of interest. Experimental interpretation should also separate receptor potency from persistence; a longer observed response does not by itself establish stronger receptor activation. Matched comparisons with short-acting analogs, repeated time points, and verification of albumin binding help assign effects to the affinity complex rather than to unrelated differences in sample quality or assay conditions. Albumin-containing controls are particularly important when experiments compare nominally equal concentrations across different media formulations.
Product page: CJC-1295 (DAC) research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.